Core Viewpoint - The collaboration between Zhejiang and Fuling has evolved over 33 years, transitioning from basic support to a comprehensive partnership that enhances industrial development and improves living standards in Fuling, showcasing a successful model of east-west cooperation in China [1][6]. Group 1: Historical Context and Development - The partnership began in 1992 with the signing of the first support agreement, aimed at aiding the Three Gorges Reservoir area, marking the start of a long-term collaboration [1]. - Over the years, Fuling has transformed from an agricultural area to an industrial hub, driven by national strategies such as the Western Development and the Chengdu-Chongqing Economic Circle [1]. Group 2: Business Environment and Investment - Fuling has made significant efforts to improve its business environment, adopting a service-oriented approach to attract and retain enterprises, exemplified by the case of Huafeng Group, which established operations in Fuling after extensive engagement [2][3]. - The region has attracted over 1,000 Zhejiang merchants and more than 290 Zhejiang enterprises, with cumulative investments exceeding 50 billion yuan, contributing to about 25% of the district's industrial output [5]. Group 3: Talent and Knowledge Exchange - The collaboration has facilitated the exchange of over 390 young cadres from Fuling to Zhejiang for training, fostering a transfer of development methodologies and governance practices [4]. - Companies like Huafeng Group have brought innovative practices and cluster development strategies to Fuling, leading to the establishment of significant production bases in the region [4]. Group 4: Social and Economic Impact - Zhejiang's support has included over 5.09 billion yuan in aid for various social projects, significantly improving living conditions in Fuling [6][7]. - Initiatives such as environmental upgrades in local communities and agricultural development have resulted in increased incomes for residents, with some households seeing annual income increases of over 6,000 yuan [7]. Group 5: Future Prospects - The partnership is set to accelerate further, with 16 new investment projects from Zhejiang planned, focusing on cutting-edge sectors like new energy and electronic information, with a total investment agreement nearing 10 billion yuan [5].

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Core Viewpoint - The company has changed its official email address for communication with investors, effective immediately from the date of the announcement [1]. Group 1: Email Change Details - The previous email address was tjzq@taiji.com, and the new email address is tjzq@sinopharm.com [1]. - Other contact information, such as office address and phone number, remains unchanged [1]. - The company requests investors to take note of the new email address and apologizes for any inconvenience caused [1].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）根据实 际工作需要，对公司电子邮箱进行变更，具体情况如下： 变更前的公司电子邮箱：tjzq@taiji.com 证券代码：600129 证券简称：太极集团 公告编号：2025-093 重庆太极实业（集团）股份有限公司 关于变更公司电子邮箱的公告 除上述变更外，公司办公地址、联系电话等其他联系方式保持不 变。变更后的电子邮箱自本公告披露之日起正式启用，原邮箱地址同 步停用，敬请广大投资者注意。由此给投资者带来的不便，敬请谅解。 欢迎广大投资者通过新的电子邮箱与公司沟通交流。 变更后的公司电子邮箱：tjzq@sinopharm.com 重庆太极实业（集团）股份有限公司 2025 年 12 月 30 日 ...

Group 1 - The core point of the announcement is that Taiji Group's shareholder, Chongqing Taiji Medicinal Plant Resources Development Co., Ltd., plans to absorb and merge its wholly-owned subsidiary, Chongqing Fuling Xilan Biotechnology Co., Ltd., with no impact on the company's control and operational independence [1][2] - The merger involves the transfer of shares: Xilan Biotechnology currently holds 11.8953 million unrestricted circulating shares, accounting for 2.157% of the total share capital of Taiji Group, which will be fully inherited by the resources company after the merger [1] - Post-merger, the resources company's shareholding in Taiji Group will increase from 367,300 shares to 12.2626 million shares, raising its ownership percentage from 0.067% to 2.224% [1] Group 2 - The merger does not involve any changes in equity increase or decrease, and the controlling shareholder, Taiji Group Co., Ltd., along with its concerted parties, will maintain a total shareholding of 1.661 billion shares, representing 30.118% [1] - The announcement clarifies that the transaction will not affect the personnel, assets, finances, business, or institutional independence of Taiji Group, and there are no circumstances that would harm the interests of the company and all shareholders [1] - Both the resources company and Xilan Biotechnology are wholly-owned subsidiaries within the Taiji Group system, with the former focusing on traditional Chinese medicine cultivation and research, while the latter is dedicated to the development and research of biopharmaceutical products [2]

Group 1 - Zhuolang Intelligent's subsidiary plans to increase capital by 900 million yuan to its wholly-owned subsidiary in Xinjiang [1] - Zhenhua Heavy Industry signed a contract worth 1.149 billion yuan with Guangzhou Salvage Bureau for a deep-water crane ship construction project [2] - Ugreen Technology intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy [3] Group 2 - Guangsheng Nonferrous Metals will change its stock name to Zhongxi Rare Metals starting December 31, 2025 [4] - China Electric Research proposed a cash dividend of 2.5 yuan per 10 shares for the first three quarters of 2025 [5] - Chaoyan Co. is establishing a fund with professional investment institutions, aiming to raise 1 billion yuan [6] Group 3 - Silk Road Vision's subsidiary plans to sell 8.5% of Ruijun Technology for 52.7 million yuan [7] - Longgao Co.'s actual controller is transferring 4.37% of the investment development group's equity for 398 million yuan [8] - Weiteou signed a strategic cooperation agreement with Huaruixin Energy to develop new materials and applications [9][10] Group 4 - Annuoqi decided to terminate the investment in a 50,000-ton dye intermediate project due to market changes, with a total investment of 421 million yuan [12] - Akoli's subsidiary has entered trial production for a project with an annual capacity of 20,000 tons of polyether amine [13] - Ningbo Construction's subsidiary signed a construction contract worth 451 million yuan for a comprehensive utility tunnel project [14] Group 5 - Zhejiang Rongtai and Weichuang Electric plan to establish a joint venture in Thailand for R&D and production of mechatronic components [15] - Jiuzhoutong's subsidiary received a drug registration certificate for isopropazine injection [16] - Huaqin Technology's subsidiary signed a daily operation contract worth 392 million yuan [17] Group 6 - ST Meichen completed the sale of 100% equity in Hainan Meichen Ecological Development Co., Ltd. [18] - Pulite's LCP film products have begun mass production for a leading customer in the consumer electronics industry [19][20] - Nanjing Public Utility's major shareholder transferred 7.61% of the company's shares for 300 million yuan [21] Group 7 - Solar Energy terminated the investment in a 150 MW distributed photovoltaic project due to increased investment risks [22] - Yuntian Lifa won a 122 million yuan project for AI development in Longgang [23] - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci141 ointment [24] Group 8 - Changfei Optical Fiber's major shareholder completed a share reduction plan, selling 1.1 million shares for approximately 104.5 million yuan [25] - Sandam Membrane plans to apply for a comprehensive credit limit of up to 100 million yuan for 2026 [26] - Aisecurity received a government subsidy of 3.4611 million yuan [27] Group 9 - Stone Technology's H-share issuance has received approval from the China Securities Regulatory Commission [28] - Hongxing Development's subsidiary plans to suspend production to comply with national hazardous chemical relocation policies [29] - Guodian Nanzi's vice president and chief engineer resigned [30] Group 10 - Jianghe Group's subsidiary won a bid for a city renovation project in Haikou worth approximately 112 million yuan [31] - Gaotie Electric's subsidiary won a bid for a railway project worth 59.0317 million yuan [32] - Huicheng Co. plans to introduce a new partner to its major shareholder [33] Group 11 - Pumen Technology's folic acid testing kit received a medical device registration certificate [34] - Hai Xin Co.'s vitamin B6 injection passed the consistency evaluation for generic drugs [35] - Taiji Group's shareholder plans to merge with its subsidiary [36] Group 12 - Shengyi Electronics adjusted the maximum repurchase price to no more than 144.36 yuan per share [37]

Core Viewpoint - Taiji Group (600129.SH) announced the planned absorption merger of its wholly-owned subsidiary, Chongqing Taiji Medicinal Plant and Animal Resources Development Co., Ltd., with another wholly-owned subsidiary, Chongqing Fuling Xilan Biotechnology Co., Ltd. This merger will not change the controlling shareholder or actual controller of the company and will not affect its independence or governance structure [1] Group 1 - The merger involves the absorption of Xilan Biotechnology, which will lead to the cancellation of Xilan's legal entity [1] - After the merger, the number of shares held by the resource company will increase from 367,271 shares to 12,262,565 shares, representing 2.224% of the company's total share capital [1] - The merger is stated to have no impact on the company's personnel, assets, finances, business, or operational independence [1]

证券代码：600129 证券简称：太极集团 公告编号：2025-092 重庆太极实业（集团）股份有限公司 关于公司股东拟被吸收合并的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 1 二、吸收合并双方基本情况 1.吸收合并方： 公司名称：重庆太极药用动植物资源开发有限公司 注册资本：16,065万元 重要内容提示： 1.本次变动系重庆太极实业（集团）股份有限公司（以下简称： 公司）股东重庆太极药用动植物资源开发有限公司拟吸收合并重庆市 涪陵区希兰生物科技有限公司发生的变动，未触及要约收购。 2.本次变动不会导致公司控股股东和实际控制人发生变化。不会 对公司人员、资产、财务、业务、机构等方面的独立性产生影响，不 会对公司治理结构及持续经营产生影响，也不存在损害公司及全体股 东利益的情形。 3.本次吸收合并尚需办理股份过户登记手续。公司将根据该事项 进展情况，严格按照有关法律法规的规定和要求履行信息披露义务。 敬请广大投资者理性投资，注意投资风险。 一、吸收合并情况概述 2025年12月26日，公司收到控股股东太极集 ...

Group 1 - The core point of the article is that Taiji Group's shareholder, Chongqing Taiji Medicinal Plant Resources Development Co., Ltd., plans to absorb and merge with Chongqing Fuling Xilan Biotechnology Co., Ltd. [1] - Upon completion of the merger, Xilan Biotechnology will be legally deregistered, and the number of shares held by the Medicinal Plant Resources Company will increase from 367,300 shares to 12,262,600 shares, representing 2.224% of the company's total share capital [1]

Group 1 - The company Taiji Group announced the public transfer of a 40% stake in its subsidiary Aida Company through a public listing, with an initial transfer price based on an assessed value of 108,000 yuan [1] - The transaction will be conducted via public listing, and there is uncertainty regarding the counterparties and final transaction price, with the company committed to timely information disclosure based on transaction progress [1] - The shareholding structure of Aida Company includes Taiji Group's subsidiary holding 40%, with other shareholders including Chongqing Dayi Technology Investment Co., Ltd. at 25%, Chongqing Taiji Camphor Tree Landscaping Engineering Co., Ltd. at 25%, and Chongqing Fuling Taiji Printing Co., Ltd. at 10% [1] Group 2 - As of December 31, 2024, Aida Company reported total assets of 13.687 million yuan, total liabilities of 16.693 million yuan, and a net asset value of -3.006 million yuan, with an operating income of 2.151 million yuan and a net loss of 780,000 yuan for the year [2] - By August 31, 2025, Aida Company's total assets decreased to 12.343 million yuan, total liabilities to 15.239 million yuan, and net assets improved slightly to -2.896 million yuan, with an operating income of 1.151 million yuan and a net loss of 1.678 million yuan for the period [2] - An asset evaluation report indicated that as of August 31, 2025, Aida Company had a total asset valuation of 15.266 million yuan, total liabilities of 15.239 million yuan, and a net asset valuation of 270,000 yuan, reflecting an increase in value of 2.923 million yuan and a growth rate of 100.93% [2]